Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
TRX Gold Reports Record Growth for Q4 and Full Year 2022; More Growth in 2023 (click to learn more) Mosaic Acquires 4 New Projects Conducive to the Discovery of Lithium (click to learn more) Gamelancer Media Announces Third Quarter Revenue of $1,330,566, Up Over 153% (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Relief Therapeutics Holding SA RLFTF

Healthcare Biotechnology
Relief Therapeutics Holding SA is a based drug development company focusing on clinical stage projects, primarily developing drugs of natural human origin. It is engaged in its operations for diabetic complications and respiratory diseases. The company is focused on developing drug candidates namely, Aviptadil and Atexakin alfa. Aviptadil is a biologically active endogenous human peptide that possesses anti-proliferative, anti-inflammatory, and immune regulatory activities. Atexakin alfa is a low dosage formulation of interleukin-6 that exhibits functions in diverse tissues and organs. The group operates its functions in Switzerland.


Recent & Breaking News (OTCQB:RLFTF)

Relief Reports that its U.S. Collaboration Partner has Announced Receipt of Initial Report of Patient Safety and Survival from Right to Try Use of Aviptadil During Omicron Surge

Accesswire January 27, 2022

Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research, Receives Notice of Allowance of Key U.S. Patent Application Covering Ready to Use Diclofenac Stick Packs

Accesswire January 24, 2022

Relief Reports US Collaboration Partner Announces Expansion of Aviptadil US Expanded Access & Right to Try Programs for Patients w/COVID-19 Respiratory Failure who've Exhausted All Approved Therapies

Accesswire January 19, 2022

Relief Therapeutics Comments on NRx Pharmaceuticals' Press Release Reporting on its Recently Filed Lawsuit

Accesswire January 14, 2022

NRx Pharmaceuticals Files Counterclaim Against its Former Collaboration Partner, Relief Therapeutics

PR Newswire January 12, 2022

Relief Comments on Lawsuit Filed Against It by NeuroRx

Accesswire January 12, 2022

Relief Reports US Collab. Partner Announces Submission to FDA seeking EUA for Aviptadil for Pts at Immediate Risk of Death from COVID-19 Despite Treatment w/Remdesivir, Other Approved Therapies

Accesswire January 6, 2022

Relief Therapeutics to Participate in Virtual Investor Conferences in January

Accesswire January 5, 2022

Relief Reports that its U.S. Collaboration Partner has Announced the Filing of a Provisional Patent Application for Stable Compositions of Aviptadil Suitable for Human Use

Accesswire January 4, 2022

Relief Therapeutics Announces Notice of Extraordinary General Meeting of RELIEF THERAPEUTICS Holding SA

Accesswire January 3, 2022

Relief Reports U.S. Collab. Partner Announces Filing Breakthrough Therapy Request for Aviptadil in Pts at Immediate Risk of Death from COVID-19 Despite Treatment w/Remdesivir, Other Approved Therapies

Accesswire December 30, 2021

Relief Reports Successful Conclusion of Patent Examination Procedure for Patent Application Entitled, 'Vasoactive Intestinal Peptide (VIP) for the Use in the Treatment of Drug-induced Pneumonitis'

Accesswire December 28, 2021

Life Sciences Companies Investor Presentations Now Available for On-Demand Viewing

PR Newswire December 20, 2021

Relief Therapeutics Files Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission

Accesswire December 16, 2021

Relief Reports that U.S. Collaboration Partner Announces New, Favorable Safety Report for Aviptadil in NIH Sponsored ACTIV-3b Critical Care Study in Patients with Life-Threatening COVID-19

Accesswire December 15, 2021

Relief Therapeutics to Webcast Live at Life Sciences Investor Forum on December 16th

PR Newswire December 10, 2021

Relief Reports that its U.S. Collaboration Partner has Agreed with Hungarian Health Officials on a Pathway for Aviptadil

Accesswire December 10, 2021

Relief Therapeutics Announces Executive Changes

Accesswire November 30, 2021

Relief Reports U.S. Collaboration Partner Identifies Significantly Higher Likelihood of Surviving & Recovering from Critical COVID-19 in Aviptadil Treated Patients Previously Administered Remdesivir

Accesswire November 29, 2021

Relief Therapeutics and InveniAI Sign a Strategic Collaboration Agreement to Identify New Product Development Opportunities using Artificial Intelligence

Accesswire November 24, 2021